Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01MBV
|
||||
| Former ID |
DNC001295
|
||||
| Drug Name |
SB-207266A
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10:A09, K58, K59.1] | Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H32ClN3O2
|
||||
| Canonical SMILES |
CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42.Cl
|
||||
| InChI |
1S/C22H31N3O2.ClH/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25;/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26);1H
|
||||
| InChIKey |
UABVCZHWRUGYSR-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 152811-62-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 4 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT4 type receptor mediated signaling pathway | |||||
| PathWhiz Pathway | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Department of Pharmacology University of Wisconsin School of Medicine. | ||||
| REF 2 | Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.